Structure Therapeutics Inc American Depositary Shares

Yahoo Finance • 11 days ago

Sum Up The Parts: ONEQ Could Be Worth $97

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • last month

Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill

Viking Therapeutics stock crashed Tuesday — losing more than a third of its value — on mixed results for its weight-loss pill. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying

Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ... Full story

Yahoo Finance • 2 months ago

Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge.

Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive positioning and Phas... Full story

Yahoo Finance • 3 months ago

We Think Structure Therapeutics (NASDAQ:GPCR) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But whi... Full story

Yahoo Finance • 3 months ago

Structure Therapeutics' SWOT analysis: oral GLP-1 stock poised for growth

Structure Therapeutics Inc. (NASDAQ:GPCR), a biopharmaceutical company specializing in the development of oral treatments for diabetes and obesity, has been making waves in the competitive GLP-1 receptor agonist market. With its lead candi... Full story

Yahoo Finance • 3 months ago

Structure Therapeutics stock maintains JMP rating ahead of key data

Investing.com - JMP Securities maintained its Market Outperform rating and $89.00 price target on Structure Therapeutics (NASDAQ:GPCR) Monday. According to InvestingPro data, analysts’ price targets range from $37.50 to $120, with the stoc... Full story

Yahoo Finance • 3 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two... Full story

Yahoo Finance • 5 months ago

Eli Lilly Soars as Oral Diabetes Pill Hits Targets in Phase 3

Eli Lilly (NYSE:LLY) shares surged around 14% in premarket trading Thursday after the company reported positive Phase 3 trial results for orforglipron, its once-daily oral GLP-1 drug for type 2 diabetes. Warning! GuruFocus has detected 6... Full story

Yahoo Finance • 6 months ago

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk(NYSE: NVO), and Viking Therapeutics(NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer's latest product announcement. Early this mo... Full story

Yahoo Finance • 8 months ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that... Full story

Yahoo Finance • last year

Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now?

We recently compiled a list of 10 Best Young Stocks To Buy Now. In this article, we will look at where Structure Therapeutics Inc. (NASDAQ:GPCR) ranks among the best young stocks to buy now. Market Uncertainty to Remain Until Elections A... Full story

Yahoo Finance • last year

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Inc. Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc.... Full story

Yahoo Finance • last year

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Structure Therapeutics Inc. SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and... Full story

Yahoo Finance • last year

Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.

With Eli Lilly up by a stunning 47% so far this year, many investors are likely prone to feeling they're stuck on the sidelines after this bull run. Even if there's plenty of upside left -- and in Eli Lilly's case, there almost certainly i... Full story

Yahoo Finance • last year

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?

Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics Inc (NASDAQ:VKTX),... Full story

Yahoo Finance • last year

Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290

Structure Therapeutics Inc. GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the capsule to tablet PK... Full story